Latest Raptor Pharmaceutical (RPTP) Headlines
Raptor Pharmaceutical to Hold Fourth Quarter and Full Year 2013 Financial Results Webcast and Conference Call
GlobeNewswire - Mon Mar 10, 6:39AM CDT
Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced that it will release fourth quarter and full year 2013 financial results after market close on Thursday, March 13, 2014. Raptor management will host a webcast and conference call at 4:30 p.m. EDT (1:30 p.m. PDT) to discuss the financial results and provide a corporate update.
Fatty Liver Disease Should Keep Stocks Moving In 2014
at Investor's Business Daily - Fri Mar 07, 4:02PM CST
One of the hottest research fields in biotech is for a disease most people have never heard of. But as data on potential treatments roll out this year, it's bound to become a lot more famous on Wall Street. Non-alcoholic steatohepatitis, or NASH,...
Raptor Pharmaceutical to Present at Two Upcoming Investor Conferences
GlobeNewswire - Mon Feb 24, 6:30AM CST
Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced that company management will present at two upcoming investor conferences.
This Week in Biotech: Buyouts, an FDA Approval, and Clinical Data. Oh, My!
Sean Williams, The Motley Fool - Motley Fool - Sat Feb 22, 11:20AM CST
With the SPDR S&P Biotech Index up 75% over the trailing-12-month period , it's evident that investment dollars are willingly flowing into the biotech sector. Keeping that in mind, let's have a look at some of the rulings, studies, and...
Raptor Soars on Positive RP103 Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Feb 21, 3:30PM CST
Raptor soared almost 14.9% after the company announced encouraging results from a study on RP103.
Biotech Stock Mailbag: Raptor, Chelsea, Oncogenex, More Hate Mail!
at The Street - Fri Feb 21, 8:03AM CST
Biotech columnist Adam Feuerstein answers readers' questions about health care companies.
Why Raptor Pharmaceuticals Corp. Shares Clawed Higher
Sean Williams, The Motley Fool - Motley Fool - Thu Feb 20, 4:06PM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Raptor Pharmaceuticals , a clinical-stage...
Major Developments and Milestones Established This Week for PetroTech, Tanke, Strategic Global, Raptor and Agenus
PR Newswire - Thu Feb 20, 12:58PM CST
Market snapshot updates and news developments for advancing cannabis and healthcare stocks: PetroTech Oil and Gas Inc. (OTC: PTOG), Tanke, Incorporated (OTC: TNKE), Strategic Global Investments, Inc. (OTC: STBV), Raptor Pharmaceutical Corp. (NASDAQ: RPTP) and Agenus Inc. (NASDAQ: AGEN).
Today's Biggest Biotech Stories: Antares Pharma Inc., BioCryst Pharmaceuticals Inc., and Raptor Phar
George Budwell, The Motley Fool - Motley Fool - Thu Feb 20, 9:02AM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. Good morning, fellow Foolish investors! It's time to check in...
Raptor Announces Clinical Results With RP103 in Huntington's Disease Phase 2/3 Trial
GlobeNewswire - Thu Feb 20, 6:00AM CST
18 Month Clinical Results Showed Significantly Slower Progression of Total Motor Score in RP103 Treated Patients Without Tetrabenazine
Leading Agencies, Paradysz And PM Digital, Highlight New Program Optimization Strategies For Nonprofit Clients At The 2014 Washington Nonprofit Conference
PR Newswire - Wed Feb 12, 7:00AM CST
Paradysz and PM Digital announced today that they are once again a patron-level sponsor of the 2014 Washington Nonprofit Conference, and will continue their tradition of leveraging this event to make key announcements around their long-standing nonprofit practice. The conference is Thursday, February 13th - Friday, February 14th at the Renaissance Washington DC Downtown Hotel located at 999 Ninth Street NW, Washington, DC.
Jim Cramer's 'Mad Money' Recap: Next Week's Game Plan
at The Street - Fri Jan 31, 6:56PM CST
The futures have a way of taking down the entire market for no particular reason, and it's times like those when investors should be buying, Cramer says.
PostageAnywhere Launches Low-Cost Postage and Shipping Platform for Small Parcel Packages
PR Newswire - Thu Jan 23, 1:20PM CST
PostageAnywhere announced today the launch of its low-cost, cloud-based postage and shipping platform for small parcel packages. The platform offers a new solution for businesses and individuals looking to ship small packages without complicated signup processes or high shipping rates.
Llew Keltner, US Biotech Industry Adviser, Joins Board of Immunovaccine
Marketwire - Mon Jan 20, 7:08AM CST
Immunovaccine Inc. ("Immunovaccine" or "IMV" or "the Company") (TSX VENTURE: IMV), a clinical stage vaccine and immunotherapy company, has elected Llew Keltner, M.D., Ph.D. to its board of directors. The appointment is effective immediately.
SarlaFlex Inc. Closes $13 Million in NMTC Financing for New U.S. Facility
Marketwire - Fri Jan 17, 8:35AM CST
SarlaFlex Inc. has secured $13 million in New Markets Tax Credit (NMTC) allocation from Los Angeles-based National New Markets Fund, LLC (NNMF) to redevelop a manufacturing facility in rural South Carolina into the company's first U.S. based yarn and thread plant. U.S. Bank serves as the tax credit investor, capitalizing the allocation.
Updates on Clinical Trial Enrollment, Product Development Updates, Clinical Collaboration, and Preliminary Sales Report - Research Report on Raptor, Synageva, XenoPort, Portola, and Zogenix
PR Newswire - Thu Jan 16, 7:00AM CST
Today, Analysts' Corner announced new research reports highlighting Raptor Pharmaceutical Corp. (NASDAQ: RPTP), Synageva BioPharma Corporation (NASDAQ: GEVA), XenoPort, Inc. (NASDAQ: XNPT), Portola Pharmaceuticals, Inc. (NASDAQ: PTLA), and Zogenix, Inc. (NASDAQ: ZGNX). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
Global Non-Alcoholic Steatohepatitis Clinical Trials Report - H2, 2013
M2 - Mon Jan 13, 10:23AM CST
Research and Markets (http://www.researchandmarkets.com/research/kv3lxq/nonalcoholic) has announced the addition of the "Non-Alcoholic Steatohepatitis Global Clinical Trials Review, H2, 2013" report to their offering. This report provides elemental information and data relating to the clinical trials on Non-Alcoholic Steatohepatitis. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Non-Alcoholic Steatohepatitis. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Top Companies Participating in Non-Alcoholic Steatohepatitis Therapeutics Clinical Trials - CATALYSIS, S.L. - Galmed International Ltd. - Genextra S.p.a. - Genfit SA - Gilead Sciences, Inc. - GlaxoSmithKline plc - Immuron Limited - LG Corp. - Phenex Pharmaceuticals AG - Raptor Pharmaceuticals Corp. Clinical Trial Overview of Top Institutes / Government - The National Institute of Diabetes and Digestive and Kidney Diseases - Tehran University of Medical Sciences - Yokohama City University - University of California, San Diego - Mayo Clinic - U.S. Department of Veterans Affairs - Hadassah Medical Organization - University of Michigan - The University of Texas Health Science Center at San Antonio - Imperial College London For more information visit http://www.researchandmarkets.com/research/kv...nalcoholic
Raptor Announces Full Enrollment of Phase 2b Trial of RP103 for Non-Alcoholic Fatty Liver Disease in Children
GlobeNewswire - Mon Jan 13, 6:00AM CST
Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced that its Phase 2b clinical trial, to evaluate the safety and potential efficacy of RP103 delayed-release cysteamine bitartrate as a prospective treatment of non-alcoholic fatty liver disease (NAFLD) in children, has met its enrollment target.
Keep a Close Watch on Synta Pharmaceuticals Corp., Raptor Pharmaceuticals Corp. and AngioDynamics, I
George Budwell, The Motley Fool - Motley Fool - Fri Jan 10, 9:15AM CST
Morning fellow, Fools! It's time to check in on some of the biggest stories in health care today. Synta moving up Synta Pharmaceuticals is making a move higher this morning following the launch of a number of clinical trials for the...
Raptor Pharmaceutical to Hold Fourth Quarter and Full Year 2013 Financial Results Webcast and Conference Call
GlobeNewswire - Mon Mar 10, 6:39AM CDT
Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced that it will release fourth quarter and full year 2013 financial results after market close on Thursday, March 13, 2014. Raptor management will host a webcast and conference call at 4:30 p.m. EDT (1:30 p.m. PDT) to discuss the financial results and provide a corporate update.
Fatty Liver Disease Should Keep Stocks Moving In 2014
at Investor's Business Daily - Fri Mar 07, 4:02PM CST
One of the hottest research fields in biotech is for a disease most people have never heard of. But as data on potential treatments roll out this year, it's bound to become a lot more famous on Wall Street. Non-alcoholic steatohepatitis, or NASH,...
Raptor Pharmaceutical to Present at Two Upcoming Investor Conferences
GlobeNewswire - Mon Feb 24, 6:30AM CST
Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced that company management will present at two upcoming investor conferences.
This Week in Biotech: Buyouts, an FDA Approval, and Clinical Data. Oh, My!
Sean Williams, The Motley Fool - Motley Fool - Sat Feb 22, 11:20AM CST
With the SPDR S&P Biotech Index up 75% over the trailing-12-month period , it's evident that investment dollars are willingly flowing into the biotech sector. Keeping that in mind, let's have a look at some of the rulings, studies, and...
Raptor Soars on Positive RP103 Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Feb 21, 3:30PM CST
Raptor soared almost 14.9% after the company announced encouraging results from a study on RP103.
Biotech Stock Mailbag: Raptor, Chelsea, Oncogenex, More Hate Mail!
at The Street - Fri Feb 21, 8:03AM CST
Biotech columnist Adam Feuerstein answers readers' questions about health care companies.
Why Raptor Pharmaceuticals Corp. Shares Clawed Higher
Sean Williams, The Motley Fool - Motley Fool - Thu Feb 20, 4:06PM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Raptor Pharmaceuticals , a clinical-stage...
Major Developments and Milestones Established This Week for PetroTech, Tanke, Strategic Global, Raptor and Agenus
PR Newswire - Thu Feb 20, 12:58PM CST
Market snapshot updates and news developments for advancing cannabis and healthcare stocks: PetroTech Oil and Gas Inc. (OTC: PTOG), Tanke, Incorporated (OTC: TNKE), Strategic Global Investments, Inc. (OTC: STBV), Raptor Pharmaceutical Corp. (NASDAQ: RPTP) and Agenus Inc. (NASDAQ: AGEN).
Today's Biggest Biotech Stories: Antares Pharma Inc., BioCryst Pharmaceuticals Inc., and Raptor Phar
George Budwell, The Motley Fool - Motley Fool - Thu Feb 20, 9:02AM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. Good morning, fellow Foolish investors! It's time to check in...
Raptor Announces Clinical Results With RP103 in Huntington's Disease Phase 2/3 Trial
GlobeNewswire - Thu Feb 20, 6:00AM CST
18 Month Clinical Results Showed Significantly Slower Progression of Total Motor Score in RP103 Treated Patients Without Tetrabenazine
Leading Agencies, Paradysz And PM Digital, Highlight New Program Optimization Strategies For Nonprofit Clients At The 2014 Washington Nonprofit Conference
PR Newswire - Wed Feb 12, 7:00AM CST
Paradysz and PM Digital announced today that they are once again a patron-level sponsor of the 2014 Washington Nonprofit Conference, and will continue their tradition of leveraging this event to make key announcements around their long-standing nonprofit practice. The conference is Thursday, February 13th - Friday, February 14th at the Renaissance Washington DC Downtown Hotel located at 999 Ninth Street NW, Washington, DC.
Jim Cramer's 'Mad Money' Recap: Next Week's Game Plan
at The Street - Fri Jan 31, 6:56PM CST
The futures have a way of taking down the entire market for no particular reason, and it's times like those when investors should be buying, Cramer says.
PostageAnywhere Launches Low-Cost Postage and Shipping Platform for Small Parcel Packages
PR Newswire - Thu Jan 23, 1:20PM CST
PostageAnywhere announced today the launch of its low-cost, cloud-based postage and shipping platform for small parcel packages. The platform offers a new solution for businesses and individuals looking to ship small packages without complicated signup processes or high shipping rates.
Llew Keltner, US Biotech Industry Adviser, Joins Board of Immunovaccine
Marketwire - Mon Jan 20, 7:08AM CST
Immunovaccine Inc. ("Immunovaccine" or "IMV" or "the Company") (TSX VENTURE: IMV), a clinical stage vaccine and immunotherapy company, has elected Llew Keltner, M.D., Ph.D. to its board of directors. The appointment is effective immediately.
SarlaFlex Inc. Closes $13 Million in NMTC Financing for New U.S. Facility
Marketwire - Fri Jan 17, 8:35AM CST
SarlaFlex Inc. has secured $13 million in New Markets Tax Credit (NMTC) allocation from Los Angeles-based National New Markets Fund, LLC (NNMF) to redevelop a manufacturing facility in rural South Carolina into the company's first U.S. based yarn and thread plant. U.S. Bank serves as the tax credit investor, capitalizing the allocation.
Updates on Clinical Trial Enrollment, Product Development Updates, Clinical Collaboration, and Preliminary Sales Report - Research Report on Raptor, Synageva, XenoPort, Portola, and Zogenix
PR Newswire - Thu Jan 16, 7:00AM CST
Today, Analysts' Corner announced new research reports highlighting Raptor Pharmaceutical Corp. (NASDAQ: RPTP), Synageva BioPharma Corporation (NASDAQ: GEVA), XenoPort, Inc. (NASDAQ: XNPT), Portola Pharmaceuticals, Inc. (NASDAQ: PTLA), and Zogenix, Inc. (NASDAQ: ZGNX). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
Global Non-Alcoholic Steatohepatitis Clinical Trials Report - H2, 2013
M2 - Mon Jan 13, 10:23AM CST
Research and Markets (http://www.researchandmarkets.com/research/kv3lxq/nonalcoholic) has announced the addition of the "Non-Alcoholic Steatohepatitis Global Clinical Trials Review, H2, 2013" report to their offering. This report provides elemental information and data relating to the clinical trials on Non-Alcoholic Steatohepatitis. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Non-Alcoholic Steatohepatitis. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Top Companies Participating in Non-Alcoholic Steatohepatitis Therapeutics Clinical Trials - CATALYSIS, S.L. - Galmed International Ltd. - Genextra S.p.a. - Genfit SA - Gilead Sciences, Inc. - GlaxoSmithKline plc - Immuron Limited - LG Corp. - Phenex Pharmaceuticals AG - Raptor Pharmaceuticals Corp. Clinical Trial Overview of Top Institutes / Government - The National Institute of Diabetes and Digestive and Kidney Diseases - Tehran University of Medical Sciences - Yokohama City University - University of California, San Diego - Mayo Clinic - U.S. Department of Veterans Affairs - Hadassah Medical Organization - University of Michigan - The University of Texas Health Science Center at San Antonio - Imperial College London For more information visit http://www.researchandmarkets.com/research/kv...nalcoholic
Raptor Announces Full Enrollment of Phase 2b Trial of RP103 for Non-Alcoholic Fatty Liver Disease in Children
GlobeNewswire - Mon Jan 13, 6:00AM CST
Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced that its Phase 2b clinical trial, to evaluate the safety and potential efficacy of RP103 delayed-release cysteamine bitartrate as a prospective treatment of non-alcoholic fatty liver disease (NAFLD) in children, has met its enrollment target.
Keep a Close Watch on Synta Pharmaceuticals Corp., Raptor Pharmaceuticals Corp. and AngioDynamics, I
George Budwell, The Motley Fool - Motley Fool - Fri Jan 10, 9:15AM CST
Morning fellow, Fools! It's time to check in on some of the biggest stories in health care today. Synta moving up Synta Pharmaceuticals is making a move higher this morning following the launch of a number of clinical trials for the...
